Prevalence of microalbuminuria in recently diagnosed Type 2 diabetes mellitus and its relationship to non-traditional risk factors: observations from the ADOPT study by Viberti, G, Freed, M, Holman, R, Lachin, J, Heise, M, Grp, A

Determinants of monotherapy failure in ADOPT - (A diabetes outcome progression trial) by Holman, R, Kahn, SE, Haffner, S, Zinman, B, Viberti, G, Herman, W, Lachin, J, Kravitz, BG, Heise, M

ADOPT: The effectiveness of metformin versus glyburide in type 2 diabetes by Herman, W, Haffner, S, Kahn, SE, Zinman, B, Holman, R, Viberti, G, Lachin, J, Kravitz, BG, Heise, M

Increased incidence of fractures in women who received rosiglitazone in ADOPT (A Diabetes Outcome Progression Trial) by Kahn, SE, Haffner, S, Lachin, J, Herman, W, Zinman, B, Holman, R, Heise, M, Aftring, R, Viberti, G

Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain by Haffner, S, Kahn, SE, Zinman, B, Holman, R, Viberti, G, Herman, W, Lachin, J, Kravitz, BG, Heise, M

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Pr... by Kahn, SE, Haffner, S, Viberti, G, Herman, W, Lachin, J, Kravitz, BG, Yu, D, Paul, G, Holman, R, Zinman, B

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. by Kahn, SE, Lachin, J, Zinman, B, Haffner, S, Aftring, R, Paul, G, Kravitz, BG, Herman, W, Viberti, G, Holman, R

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. by Lachin, J, Viberti, G, Zinman, B, Haffner, S, Aftring, R, Paul, G, Kravitz, BG, Herman, W, Holman, R, Kahn, SE

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). by Kahn, SE, Zinman, B, Lachin, J, Haffner, S, Herman, W, Holman, R, Kravitz, BG, Yu, D, Heise, M, Aftring, R, Viberti, G

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. by Zinman, B, Haffner, S, Herman, W, Holman, R, Lachin, J, Kravitz, BG, Paul, G, Jones, N, Aftring, R, Viberti, G, Kahn, SE

Rosiglitazone-associated fractures in type 2 diabetes by Kahn, SE, Zinman, B, Lachin, J, Haffner, S, Herman, W, Holman, R, Kravitz, BG, Yu, D, Heise, M, Aftring, R, Viberti, G

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. by Kahn, SE, Haffner, S, Heise, M, Herman, W, Holman, R, Jones, N, Kravitz, BG, Lachin, J, O'Neill, M, Zinman, B, Viberti, G

Changes in bone metabolism biomarkers in the ADOPT study by Kahn, SE, Herman, W, Holman, R, Haffner, S, Zinman, B, Aftring, R, Kravitz, BG, Paul, G, Jones, N, Lachin, J, Viberti, G, Grp, A

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. by Kahn, SE, Zinman, B, Haffner, S, O'Neill, M, Kravitz, BG, Yu, D, Freed, M, Herman, W, Holman, R, Jones, N, Lachin, J, Viberti, G

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2... by Viberti, G, Kahn, SE, Greene, D, Herman, W, Zinman, B, Holman, R, Haffner, S, Levy, D, Lachin, J, Berry, R, Heise, M, Jones, N, Freed, M

A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2... by Viberti, G, Kahn, SE, Greene, D, Herman, W, Zinman, B, Holman, R, Haffner, S, Levy, D, Lachin, J, Berry, R, Heise, M, Jones, N, Freed, M

Pancreatic safety of sitagliptin in the TECOS Study. by Buse, J, Bethel, M, Green, J, Stevens, S, Lokhnygina, Y, Aschner, P, Grado, C, Tankova, T, Wainstein, J, Josse, R, Lachin, J, Engel, S, Patel, K, Peterson, E, Holman, R, TECOS Study Group

Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial by McGuire, D, Van De Werf, F, Armstrong, P, Standl, E, Koglin, J, Green, J, Bethel, M, Cornel, J, Lopes, R, Halvorsen, S, Ambrosio, G, Buse, J, Josse, R, Lachin, J, Pencina, M, Garg, J, Lokhnygina, Y, Holman, R, Peterson, E